G protein-coupled receptor kinase (GRK) specificity of endogenous type 1 vasoactive intestinal polvpeptide (VIP) receptor expressed on the surface of HEK 293 cells

2000 ◽  
Vol 118 (4) ◽  
pp. A309
Author(s):  
Michael A. Shetzline ◽  
Julia K. Walker ◽  
Brian M. Curtin ◽  
Richard T. Premont ◽  
Marc G Caron
Endocrinology ◽  
2007 ◽  
Vol 148 (7) ◽  
pp. 3236-3245 ◽  
Author(s):  
E. Filardo ◽  
J. Quinn ◽  
Y. Pang ◽  
C. Graeber ◽  
S. Shaw ◽  
...  

G protein-coupled receptor 30 (GPR30), a seven-transmembrane receptor (7TMR), is associated with rapid estrogen-dependent, G protein signaling and specific estrogen binding. At present, the subcellular site of GPR30 action is unclear. Previous studies using antibodies and fluorochrome-labeled estradiol (E2) have failed to detect GPR30 on the cell surface, suggesting that GPR30 may function uniquely among 7TMRs as an intracellular receptor. Here, we show that detectable expression of GPR30 on the surface of transfected HEK-293 cells can be selected by fluorescence-activated cell sorting. Expression of GPR30 on the cell surface was confirmed by confocal microscopy using the lectin concanavalin A as a plasma membrane marker. Stimulation of GPR30-expressing HEK-293 cells with 17β-E2 caused sequestration of GPR30 from the cell surface and resulted in its codistribution with clathrin and mobilization of intracellular calcium stores. Evidence that GPR30 signals from the cell surface was obtained from experiments demonstrating that the cell-impermeable E2-protein conjugates E2-BSA and E2-horseradish peroxidase promote GPR30-dependent elevation of intracellular cAMP concentrations. Subcellular fractionation studies further support the plasma membrane as a site of GPR30 action with specific [3H]17β-E2 binding and G protein activation associated with plasma membrane but not microsomal, or other fractions, prepared from HEK-293 or SKBR3 breast cancer cells. These results suggest that GPR30, like other 7TMRs, functions as a plasma membrane receptor.


Endocrinology ◽  
2006 ◽  
Vol 147 (1) ◽  
pp. 441-450 ◽  
Author(s):  
Kazunori Kageyama ◽  
Komaki Hanada ◽  
Takako Moriyama ◽  
Takeshi Nigawara ◽  
Satoru Sakihara ◽  
...  

2008 ◽  
Vol 31 (7) ◽  
pp. 1455-1464 ◽  
Author(s):  
Junichi YATABE ◽  
Hironobu SANADA ◽  
Sanae MIDORIKAWA ◽  
Shigeatsu HASHIMOTO ◽  
Tsuyoshi WATANABE ◽  
...  

2007 ◽  
Vol 101 (1) ◽  
pp. 192-204 ◽  
Author(s):  
Jun Yu ◽  
David Lubinsky ◽  
Natia Tsomaia ◽  
Zhenhua Huang ◽  
Linda Taylor ◽  
...  

2004 ◽  
Vol 182 (1) ◽  
pp. 173-182 ◽  
Author(s):  
C Voigt ◽  
HP Holzapfel ◽  
S Meyer ◽  
R Paschke

G-protein-coupled receptor kinases (GRKs) are implicated in the pathophysiology of human diseases such as arterial hypertension, heart failure and rheumatoid arthritis. While G-protein-coupled receptor kinases 2 and 5 have been shown to be involved in the desensitization of the rat thyrotropin receptor (TSHR), their role in the pathophysiology of hyperfunctioning thyroid nodules (HTNs) is unknown. Therefore, we analyzed the expression pattern of the known GRKs in human thyroid tissue and investigated their function in the pathology of HTNs. The expression of different GRKs in human thyroid and HTNs was measured by Western blotting. The influence of GRK expression on TSHR function was analyzed by coexpression experiments in HEK 293 cells. We demonstrate that in addition to GRKs 2, 5 and 6, GRKs 3 and 4 are also expressed in the human thyroid. GRKs 2, 3, 5 and 6 are able to desensitize the TSHR in vitro. This GRK-induced desensitization is amplified by the additional over-expression of beta-arrestin 1 or 2. We did not find any mutations in the GRKs 2, 3 and 5 from 14 HTNs without TSHR mutations and Gsalpha mutations. The expression of GRKs 3 and 4 was increased in HTNs independently from the existence of TSHR mutations or Gsalpha mutations. In conclusion, the increased expression of GRK 3 in HTNs and the ability of GRK 3 to desensitize the TSHR in vitro, suggest a potential role for GRK 3 as a negative feedback regulator for the constitutively activated cAMP pathway in HTNs.


2004 ◽  
Vol 141 (1) ◽  
pp. 141-151 ◽  
Author(s):  
Kerstin Wirkner ◽  
Joana Schweigel ◽  
Zoltan Gerevich ◽  
Heike Franke ◽  
Clemens Allgaier ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document